Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Lifecore Biomedical Clears HSR Antitrust Waiting Period for Parent Merger

Neutral Impact 3 of 5 m&a Written later

Lifecore Biomedical said the U.S. Department of Justice and Federal Trade Commission granted early termination of the HSR Act waiting period on November 4, 2026, satisfying one closing condition of its pending merger with Lifecore Inc. The merger still requires other conditions and approvals, including stockholder adoption of the merger agreement at a special meeting.

Key points

  • Early termination of the HSR Act waiting period granted effective November 4, 2026
  • Merger agreement with Lifecore Inc. and Hazel Merger Sub, Inc. was signed September 27, 2026
  • Stockholder approval at a special meeting and other closing conditions remain outstanding
  • Company filed a preliminary proxy statement; a definitive proxy statement is still planned

The filing

CompanyLIFECORE BIOMEDICAL, INC. \DE\ (LFCR)
Form8-K, current report
Filed with the SECNov 5, 2026, 8:02 AM ET
Accession number0001005286-26-000049

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.